Hormonal therapy of gender dysphoria: The male-to-female transsexual

Current Concepts in Transgender Identity

Volumn , Issue , 2013, Pages 277-296

  Basson, Rosemary ^a   Prior, Jerilynn C ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85073854119     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.4324/9780203775134-28     Document Type: Chapter

References (29)

1. Asschcman, H. (1989). Cross-gender hormone treatment, side effects and some metabolic aspects. Ph.D. Thesis, Centrale Hussdrukkerij Vrije Lemierscteit, (Amsterdam), pp. 1-113.
2. Asscheman, H., & Gooren, L.J. (1992). Hormone treatment in transsexuals, journal of Psychology & Human Sexuality, S, 39-54.
3. Asscheman, H., Gooren, L.J., & Eklund, P.L. (1989). Mortality and morbidity in transsexual patients with cross-gender hormone treatment. Metabolism, 38, 869-873.
4. Clarke, C.L., & Sutherland, R.L. (1990). Progestin regulation of cellular proliferation. Endocrine Review, 11, 266-301.
5. Coronary Drug Project Research Group. (1970). Coronary drug project: Initial findings leading to modifications of its research protocol, journal of the American Medical Association, 214, 1303-1313.
6. Coronary Drug Project Research Group. (1973). Coronary drug project: Findings leading to the discontinuation of the 2.5 mg/day estrogen group. Journal of the American Medical Association, 226, 652-657.
7. Corrol, P., Michaud, A., Menard, J., Freifeld, M., et al. (1975). Anti-androgenic effect of spironolactone: Mechanism of action. Endocrinology, 97, 52-58.
8. de Vries, C.P., Gooren, L.J., & van der Veen, E.A. (1986). The effect of cyproterone acetate alone and in combination with ethinylestradiol on the hypothalamic pituitary adrenal axis, prolactin and GH release in male-to-femalc transsexuals. Hormones, Metabolism, and Research, 18, 203-205.
9. Gallagher, J.C., Kable, W.T., & Goldgar, D. (1991). The effect of progestin therapy on cortical and trabecular bone: Comparison with estrogen. American Journal of Medicine, 90, 171-178.
10. Goh, H.H., Li, X.F., & Ratnam, S.S. (1992). Effects of cross-gender steroid hormone treatment on prolactin concentrations in humans. Gynecology and Endocrinology, 6, 113-117.
11. Goh, H.H., & Ratnam, S.S. (1990). Effect of estrogens on prolactin in secretion in transexual subjects. Sex and Behavior, 19, 507-516.
12. Grady, D., Rubin, S.M., Petitti, D.B., Fox, C.S., et al. (1992). Hormone therapy to prevent disease and prolong life in postmenopausal women. Annals of Internal Medicine, 117, 1016-1037.
13. Hargrove, J.T., Maxon, W.S., Wentz, A.C., & Burnett, A.L. (1989). Menopausal hormone replacemen’ therapy with continuous daily oral micronized estradiol and progesterone. Obstetrics & Gynecology, 73, 606-612.
14. Kovacs, K., Stetaneanu, L., Ezzat, S.D., & Smyth, H.S. (1994). Prolactin-producing pituitary adenoma in a male-to-female transsexual patient with protracted estrogen administration: A morphological study. Archives of Pathology and Laboratory Medicine, 118, 562-565.
15. Lips, P., Asscheman, H., Uitewall, P., Netelenbos, J.C., et al. (1989). The effects of cross-gender hormonal treatment on bone metabolism in male-to-female transsexuals. Journal of Bone Mineral Metabolism, 4, 657-662.
16. Meyer, W.J., Finkelstein, J.W., Stuart, L.A., Webb, A., et al. (1981). Physical and hormonal evaluation of transsexual patients during hormonal therapy. Archives of Sexual Behavior, 10, 347.
17. Meyer, W.J., Webb, A., Stuart, C.A., Finkelstein, J.W., et al. (1986). Physical and hormonal evaluation of transsexual patients: A longitudinal study. Archives of Sexual Behavior, 15, 121-138.
18. New, M.I., & Ketzinger, E.S. (1993). Pope Joan: A recognizable syndrome. Journal of Clinical Endocrinology and Metabolism, 76, 3-13.
19. Orwoll, E.S., & Klein, R.F. (1995). Osteoporosis in men. Endocrine Review, 16, 87116.
20. Pate, R.R., Pratt, M., Blair, S.N., Haskell, W.L., et al. 1995. Physical activity and public health: A recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. Journal of the American Medical Association, 273, 402-407.
21. Powell, K.E., Thompson, P.D., Casperscn, C.J., & Kendrick, J.S. (1987). Physical activity and the incidence of coronary heart disease. Annual Review of Public Health, 8, 253-287.
22. Prior, J.C. (1990). Progesterone as a bone-trophic hormone. Endocrine Review, 11, 386-398.
23. Prior, J.C., Alojado, N., McKay, D.W., & Vigna, Y.M. (1994). No adverse effects of medroxyprogesterone treatment without estrogen in postmenopausal women: Double-blind, placebo-controlled, cross-over trial. Obstetrics & Gynecology, 83, 24-28.
24. Prior, J.C., Vigna, Y.M., Barr, S.I., Rexworthy, C, et al. (1994). Cyclic medroxyprogesterone treatment increases bone density: A controlled trial in active women with menstrual cycle disturbances. American Journal of Medicine, 96, 521-530.
25. Prior, J.C., Vigna, Y.M., & Watson, D. (1989). Spironolactone with physiological female gonadal steroids in the prcsurgical therapy of male to female transsexuals: A new observation. Archives of Sexual Behavior, 18, 49-57.
26. Prior, J.C., Vigna, Y.M., Watson, D., & Dicwold, P. (1986). Spironolactone in the presurgical therapy of male to female transsexuals: Philosophy and experience of the Vancouver Gender Dysphoria Clinic. Journal of the Sex Information and Education Council of Canada, 1, 1-7.
27. Pritchard, J.J., Pankowsky, D.A., Crowe, J.P., & Abdul-Karim, F.W. (1988). Breast cancer in a male-to-female transsexual. Journal of the American Medical Association, 259, 2278-2280.
28. Schiff, I., Tulchinsky, D., Cramer, D., ÔC Ryan, K.J. (1980). Oral medroxyprogesterone in the treatment of postmenopausal symptoms. Journal of the American Medical Association, 244, 1443-1445.
29. Writing group for PEPI trial. (1995). Effects of estrogen and estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The postmenopausal estrogen/progestin interventions (PEPI) trial. Journal of the American Medical Association, 273, 199-208.